The Food and Drug Administration, which issued its proposal in November, said the change is designed to "create parity" between branded and generic drug makers with respect to labeling changes ...

The proposal would allow insurers to only credit the cost of a generic drug -- if one exists -- toward the annual limit for cost-sharing. So if a consumer filled a prescription with a $25 brandname ...